利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.02 秒)

    Bicyclic and tricyclic derivatives as thrombin receptor antagonists
    2.
    发明授权
    Bicyclic and tricyclic derivatives as thrombin receptor antagonists 有权
    双环和三环衍生物作为凝血酶受体拮抗剂

    公开(公告)号：US08153664B2

    公开(公告)日：2012-04-10

    申请号：US11865793

    申请日：2007-10-02

    申请人： Samuel Chackalamannil ,  Mariappan V. Chelliah ,  Yuguang Wang ,  Yan Xia

    发明人： Samuel Chackalamannil ,  Mariappan V. Chelliah ,  Yuguang Wang ,  Yan Xia

    IPC分类号： C07D401/06 ,  A61K31/4439 ,  A61P7/02 ,  A61P7/12 ,  A61P9/10 ,  A61P29/00 ,  A61P19/02 ,  A61P3/10 ,  A61P3/14 ,  A61P11/06 ,  A61P11/08

    CPC分类号： C07D401/06 ,  C07D417/06

    摘要： Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    摘要翻译： 所述式的杂环取代三环或所述化合物，异构体或外消旋混合物的药学上可接受的盐或溶剂合物，其中代表任选的双键，虚线任选是键或无键，导致双键或单键， 如价格要求所允许的，其中E，A，GM，Het，B，X，R 3，R 10，R 11，R 32和R 33在本文中定义，其余取代基如说明书中所定义，以及药物 含有它们的组合物和通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。 还要求与其它心血管药物联合治疗。

    Substituted bicyclic and tricyclic thrombin receptor antagonists
    4.
    发明授权
    Substituted bicyclic and tricyclic thrombin receptor antagonists 有权
    取代的双环和三环凝血酶受体拮抗剂

    公开(公告)号：US08022088B2

    公开(公告)日：2011-09-20

    申请号：US11769018

    申请日：2007-06-27

    申请人： Mariappan V. Chelliah ,  Samuel Chackalamannil ,  Yan Xia

    发明人： Mariappan V. Chelliah ,  Samuel Chackalamannil ,  Yan Xia

    IPC分类号： A01N43/40 ,  A61K31/44 ,  C07D405/00

    CPC分类号： C07D405/06

    摘要： Substituted bicyclic and tricyclic modified himbacine derivative of the formula: or a pharmaceutically acceptable salt or solvate of said compound wherein represents an optional double bond and wherein En, Fn, Gn, Zn, Jn, X, R3, R9, R10, R11, R32, R33, B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other agents is also claimed.

    摘要翻译： 其中代表任选的双键的取代的双环和三环修饰的烟草衍生物，或其药学上可接受的盐或溶剂化物，其中En，Fn，Gn，Zn，Jn，X，R3，R9，R10，R11，R32 本文定义的R33，B和Het以及含有它们的药物组合物和通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病的方法。 还声称与其他药剂组合治疗。

    Fused ring thrombin receptor antagonists
    5.
    发明授权
    Fused ring thrombin receptor antagonists 有权
    融合环凝血酶受体拮抗剂

    公开(公告)号：US08372980B2

    公开(公告)日：2013-02-12

    申请号：US13188520

    申请日：2011-07-22

    申请人： Mariappan V. Chelliah ,  Samuel Chackalamannil

    发明人： Mariappan V. Chelliah ,  Samuel Chackalamannil

    IPC分类号： C07D413/00 ,  A01N43/04 ,  A01N43/40 ,  A01N43/42 ,  A61K31/70 ,  A61K31/44 ,  A61K31/727

    CPC分类号： C07D405/06 ,  C07D498/04

    摘要： Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein  represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    摘要翻译： 具有下式的稠环，杂环取代的三环或所述化合物的药学上可接受的盐或溶剂合物，异构体或外消旋混合物，其中表示任选的双键，并且其中An，En，Mn，Gn，Jn，R 3，n 7，R 8 本文定义了R9，R10，R11，R32，R33，X，Y，B和Het，其余取代基如说明书中所定义，以及含有它们的药物组合物以及治疗与 血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症。 还要求与其它心血管药物联合治疗。

    Fused Ring Thrombin Receptor Antagonists
    7.
    发明申请
    Fused Ring Thrombin Receptor Antagonists 有权
    融合环凝血酶受体拮抗剂

    公开(公告)号：US20070244163A1

    公开(公告)日：2007-10-18

    申请号：US11734057

    申请日：2007-04-11

    申请人： Yan Xia ,  Mariappan V. Chelliah ,  Samuel Chackalamannil

    发明人： Yan Xia ,  Mariappan V. Chelliah ,  Samuel Chackalamannil

    IPC分类号： A61K31/4439 ,  C07D491/02

    CPC分类号： C07D405/06 ,  C07D498/04

    摘要： Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    摘要翻译： 熔融环，具有下式的杂环取代的三环或所述化合物的药学上可接受的盐或溶剂合物，异构体或外消旋混合物，其中表示可选的双键，并且其中A N，N， M，N，N，N，N，N，N，N，N， R 8，R 9，R 10，R 11，R 32，R 12， 本文中定义了R32，X，Y，B和Het，其余取代基如说明书中所定义，以及含有它们的药物组合物和 通过施用所述化合物治疗与血栓形成，动脉粥样硬化，再狭窄，高血压，心绞痛，心律失常，心力衰竭和癌症相关的疾病。 还要求与其它心血管药物联合治疗。